Biotech Startups

GeniPhys develops Collymer, a patented polymerizable (scaffold-forming) collagen technology used to design and fabricate collagen biomaterials for tissue restoration and regeneration. Its materials target regenerative medicine applications including soft tissue, cardiovascular, musculoskeletal, and orthopedic replacements, as well as delivery of pharmaceutical and cell-based therapies and device coatings.

1 investor

1 investor

Genomadix develops the Cube, a point-of-care PCR platform for real-time molecular testing in precision medicine and environmental applications. The company commercializes FDA-cleared genotyping tests and offers its open platform for partnerships with assay developers and clinical laboratories.

1 investor

Genomate Health develops an AI-powered clinical decision support system for precision oncology that analyzes a patient's molecular profile to produce evidence-based treatment rankings for physicians. Its Genomate platform combines oncology, genomics, and computational reasoning to support personalized cancer treatment decisions.

1 investor

Genomatica (Geno) develops biotechnology processes to produce bio-based chemicals and materials—such as 1,4-butanediol (BDO), butylene glycol for cosmetics, and plant-based nylon—as alternatives to fossil-fuel-derived inputs. It licenses and scales these technologies with industrial partners across the chemicals, beauty, and materials industries in the US, Europe, and Asia.

1 investor

Genome Medical provides telehealth-enabled genetic counseling, testing, and clinical trial access for patients with rare diseases. The company partners with hospitals, health systems, and life sciences organizations to deliver expert genetic services at scale.

1 investor

GenoME develops liquid biopsy tests using DNA methylation biomarkers for early disease detection and monitoring, particularly in cancer diagnostics. The company's pipeline identifies novel biomarkers and delivers rapid, cost-effective PCR tests for applications including companion diagnostics and disease monitoring.

1 investor

Omzey (formerly GenomeUp) develops JuliaOmix, a diagnostic suite designed to accelerate the diagnosis of rare diseases using omics sciences. The company serves clinicians, researchers, and patients working in rare disease diagnostics and precision medicine.

1 investor

GenomeMiner develops A.I.-driven bioinformatics and genome mining software, using DNA sequencing and proprietary data from organisms in subtropical Okinawa to identify and produce valuable natural products. Originally founded as Tupac.Bio building tools for synthetic biology companies, it aims to serve the biotech industry and eventually develop its own end-products.

1 investor

Genomic Vision is a genome analysis company whose Molecular Combing technology characterizes DNA at single-molecule resolution for quality control in bioproduction and cell and gene therapy, as well as for drug discovery research. It serves pharmaceutical, biotech, and research organizations developing gene therapies and studying DNA replication.

1 investor

GenomicMD provides clinical-grade genomic risk assessments to physicians for integrating personalized medicine into patient care, using polygenic analysis to identify disease risk and guide preventive health management. The company serves medical practices and patients seeking evidence-based genetic screening beyond traditional family history assessments.

1 investor

Genomics is a genetics company that uses polygenic risk scores and DNA analysis to predict an individual's risk of common diseases, offering risk assessment tools through a single at-home test. It serves insurance and other partners, employers, life sciences and pharmaceutical companies, and healthcare systems for disease prediction, drug discovery, and precision health.

1 investor

GenomILL develops precision diagnostic technologies using genomic analysis. The company serves clinical and research customers seeking advanced molecular diagnostics.

1 investor

GenMedPro is a genetics-based medication management platform that analyzes 26 genes to identify drug-drug and gene-drug interactions across a patient's entire medication regimen. The platform serves healthcare providers and care teams to reduce prescribing errors, prevent adverse events, and optimize medication safety for complex polypharmacy cases.

1 investor

GenomOncology builds precision oncology software, including its Precision Oncology Platform (POP) and a Pathology Workbench, along with content and curation data products for clinical genomics. It serves clinicians and researchers in cancer care through healthcare IT and bioinformatics tools.

1 investor

GenomSys develops modular software for storing, processing and sharing genomic data based on the ISO/IEC 23092 MPEG-G standard, serving diagnostic laboratories, hospitals, research centers and biotech companies. The company operates in computational genomics and precision medicine, with a Swiss parent company and an Italian subsidiary running its MPEG-G Competence Center in Milan.

1 investor

Genomtec develops a mobile platform for point-of-care genetic diagnostics that detects respiratory pathogens including viruses and bacteria. The company has obtained CE-IVD certification for its respiratory diagnostic panel in Europe.

1 investor

Genoskin offers MANTIS, a spatial biology platform that performs multiplex 3D imaging analysis of human skin tissue to study immune cell responses to vaccines, drugs, and cosmetics. The platform enables automated, unbiased profiling of immune cells within their tissue context using fluorescence-based imaging and proprietary computational analysis.

1 investor

Genotix Bio develops the DaVinci, a compact nanoarray analyzer that detects proteins and nucleic acids at single-molecule resolution for research applications. The instrument enables ultrasensitive biomarker detection with minimal sample volumes and fast processing times.

1 investor

GenScript Biotech is a life sciences company providing reagents, custom services, instruments, and biologics development solutions to research and pharmaceutical industries globally. The company operates through subsidiaries including Bestzyme (synthetic biology), ProBio (biologics CDMO), and GenScript Life Science Group, with manufacturing and R&D centers across China, Singapore, and the United States.

1 investor

GenVault operates a GxP-compliant biorepository providing secure, temperature-controlled storage, sample management, and lab relocation services for biological, clinical, and biopharmaceutical materials. It serves pharma, biotech, academia, CROs, CDMOs, and government clients, offering ambient/CRT, cold room, freezer/ULT, and cryogenic storage backed by ISO, CAP, and FDA certifications.

1 investor

GenWorks manufactures medical devices for patient monitoring and care support across ICU, critical care, operating theater, and maternal-newborn care settings. The company produces infusion pumps, defibrillators, anesthesia machines, ventilators, and related monitoring equipment for hospitals and healthcare facilities.

1 investor

Genyro develops a DNA writing and assembly platform based on its Sidewinder technology and "page-number" barcode logic, which directs precise joining of DNA fragments to build genomes and constructs from any designed sequence. The company targets applications in biomanufacturing, programmable therapeutics, and large-scale genome and protein design for the bioeconomy.

1 investor

George Medicines develops single-pill combination therapies for cardiometabolic diseases such as hypertension and diabetes, leveraging research from The George Institute for Global Health. The company targets patients with low medication adherence and aims to reduce the burden of non-communicable diseases on patients, families, and health systems.

1 investor